CJC1295 with DAC – 5mg

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH) designed for extended pharmacokinetic duration. Unlike its modified GRF (1-29) counterpart, this compound includes a non-peptidic Drug Affinity Complex linked to the C-terminus, which allows it to bind covalently to endogenous albumin after administration. This structural modification prevents rapid renal clearance and enzymatic degradation, stretching its half-life from minutes to several days and shifting growth hormone (GH) secretion from a pulsatile pattern to a continuous, elevated baseline.

Key Features & Characteristics

• Mechanism of Action: Binds to GHRH receptors on pituitary somatotropes while utilizing albumin hitchhiking to maintain continuous receptor activation.
• Extended Pharmacokinetics: Features the specialized DAC modification, extending the peptide’s biological half-life significantly to up to 8 days in animal models.
• Basal Secretion Shift: Alters standard physiological rhythms by replacing natural, periodic GH spikes with a sustained, constant release profile.
• Physical Form: Synthesized as a highly stable, ultra-pure lyophilized powder engineered to withstand ambient shipping profiles prior to liquid reconstitution.

Primary Research Applications

• Sustained Somatotropic Signaling: Investigated to evaluate the long-term biological effects and receptor desensitization limits of constant growth hormone exposure.
• Trophic Factor Optimization: Studied for its capacity to induce steady, prolonged elevations in systemic Insulin-like Growth Factor 1 (IGF-1) levels with minimal intervention frequency.
• Chronic Tissue & Muscle Degradation: Evaluated in long-term wasting models to observe sustained nitrogen retention, protein synthesis, and lean mass preservation over extended experimental timelines.

For Research Use Only. Not for human consumption, therapeutic, or diagnostic use.